Barclays Initiates Coverage On Minimed Group with Overweight Rating, Announces Price Target of $26
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Barclays analyst Matt Miksic initiates coverage on Minimed Group (NASDAQ:MMED) with a Overweight rating and announces Price Target of $26.
Barclays analyst Matt Miksic initiates coverage on Minimed Group (NASDAQ:MMED) with a Overweight rating and announces Price Target of $26.